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Abstract: Aspiration pneumonia is a major cause of death in patients with dysphagia, often 
accompanied by psychiatric symptoms. The inhibition of swallowing and cough reﬂ  exes, which 
contribute to a signiﬁ  cant risk for aspiration, may be related to decreased levels of substance P. 
Clinical studies indicate a strong association of an increased mortality in psychiatric patients 
with the use of antipsychotics. The present study documented fewer positive episodes of swal-
lowing reﬂ  ex in patients treated with haloperidol for schizophrenia (7/11; 63.6%) than those 
treated with risperidone (10/11; 90.9%). In addition, patients treated with risperidone had serum 
substance P levels comparable with control subjects (29.0 ± 7.8 pg/mL, 29.6 ± 7.6, respectively; 
p = 0.9), while patients treated with haloperidol had signiﬁ  cantly lower serum substance P levels 
(20.6 ± 5.5 pg/mL; p   0.01). Among patients on haloperidol, those with negative episodes of 
reﬂ  ex (4/11; 36.4%) had serum substance P levels at 15.8 ± 1.0 pg/mL, in contrast with those 
with positive episodes (7/11; 63.6%) who had serum levels at 23.4 ± 4.9 pg/mL. However, in 
the patient group treated with risperidone, serum substance P levels in the majority of patients 
with positive episodes of reﬂ  exes (10/11, 90.9%; 30.1 ± 7.2 pg/mL) was found to be as high as 
in control subjects, all with positive episodes (5/5, 100%; 29.6 ± 7.6 pg/mL) (p = 0.866), and 
higher than in one patient with negative reﬂ  ex (1/11, 9.1%; 18.0 ± 0.0 pg/mL). These results 
suggest that the decreased serum substance P levels are strongly associated with the use of 
haloperidol, as well as decreased swallowing reﬂ  exes. This suggests that serum substance P 
levels may be a useful predictive marker for the increased risk of developing aspiration, or sub-
sequently aspiration pneumonia. Moreover, this increased incidence of aspiration may contribute 
to an increased mortality in patients following antipsychotic therapy. Risperidone, which has 
little inﬂ  uence on serum substance P productions, may be a more appropriate ﬁ  rst-line drug of 
choice for treatment of schizophrenia
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Introduction
Aspiration pneumonia is a major cause of death in elderly patients over 60 years old, 
especially with dysphagia, often accompanied by psychiatric or underlying causes 
(Haleem 1990; Elpern 1997; Fioritti et al 1997). It has recently been shown that the use 
of antipsychotic drugs is linked to increased risk of death among the elderly patients 
with dementia and neuropsychiatric symptoms (Schneider et al 2005; Rabins and 
Lyketsos 2005; Wang et al 2005). Moreover, retrospective analyses suggest that typical 
antipsychotics seemed to be associated with a higher risk for death than are atypical 
antipsychotics (Nasrallah et al 2004; Wang et al 2005). Deaths in these clinical trials 
seem to have been primarily related to cardiac arrhythmias and aspiration pneumonia 
(Pontoppidant and Beecher 1960; Nakagawa et al 1993; FDA 2006). The majority 
of patients who aspirate have clinically silent aspiration with no recognizable signs 
or symptoms (Linden and Siebens 1983; Pikus et al 2003). Silent aspiration remains Neuropsychiatric Disease and Treatment 2008:4(1) 290
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a major clinical problem, because the clinical history is not 
beneﬁ  cial in determining patients at a risk for the development 
of aspiration pneumonia (Logemann 1983; Pikus et al 2003). 
In fact, it has been shown that silent aspiration associated with 
impaired swallowing and cough reﬂ  exes in the elderly leads 
to a high risk of developing aspiration pneumonia (Horner 
and Massey 1988; Holas et al 1994). In other word, the risk of 
developing aspiration pneumonia may be substantially higher 
in patients with silent aspiration compared with those in whom 
aspiration elicits reﬂ  exes. Therefore, the use of antipsychotic 
medications in elderly patients may increase development 
of silent aspiration, or aspiration pneumonia leading to an 
increased risk of mortality in this patient group.
Substance P has been shown to be the natural endogenous 
ligand of tachykinin NK1 receptors that control the swallow-
ing and cough reﬂ  exes (Regoli et al 1994; Yamaya et al 2001; 
Zachrisson et al 2000). Tachykinins which act on NK recep-
tors have implications for the clinical use of NK receptor 
antagonists in schizophrenia (Chahl 2006). Administration 
of haloperidol signiﬁ  cantly decreases substance P-encoding 
mRNAs, suggesting a drug-induced decrease in nigrostriatal 
tachykinin biosynthesis (Bannon et al 1986). Thus, the use 
of haloperidol might contribute to a lowering of serum sub-
stance P levels in psychotic patients, and this depression of 
substance P production might be a major risk for developing 
aspiration in the elderly because of the associated impaired 
swallowing and cough reﬂ  ex with senescence. Taking these 
results into consideration, it is hypothesized that the increased 
risk of death in elderly patients, associated with the use of 
antipsychotics and the resulting decrease in substance P lev-
els, might be attributable to the increased risk of developing 
silent aspiration, or potentially aspiration pneumonia.
The present study was undertaken to examine the rela-
tionship of serum substance P levels with antipsychotic drug 
use and with the risk of developing aspiration, or aspiration 
pneumonia in patients with chronic schizophrenia.
Methods
Subjects
The Ethical Committee of Seiwakai-Kitsunan Hospital 
reviewed and approved this study protocol. All participants 
gave their written informed consent. The investigations 
were performed according to the principles expressed in 
the Declaration of Helsinki. Twenty-two patients, 49–74 
year-old, both males and females, and diagnosed with schizo-
phrenia by DMS-IV criteria, were treated with risperidone 
or haloperidol monotherapy for a minimum of 1 year. Five 
demographically matched control subjects were included in 
this study. The exclusion criteria were (1) cerebral infarction 
(veriﬁ  ed by X-ray computed tomographic scan of the brain) 
and (2) bronchial asthma.
Measurements of serum substance P
Isolation of serum samples
The peripheral blood samples were mixed with EDTA-2Na 
immediately after drawn, followed by the addition of aprotinin to 
avoid degradation of substance P. Samples were then centrifuged 
at 4 °C. The resulting plasma was stored at  –20 °C until assay. An 
aliquot of 0.5 mL plasma sample was mixed with 1 mL acetone 
and then centrifuged at 3000 rpm at 4 °C for 10 minutes. 
The supernatant was delipidized with 1 mL petroleum ether 
and the upper layer was discarded. This manipulation was 
executed twice. The lower layer was evaporated by nitrogen 
gas at 45 °C and reconstituted with 0.25 mL assay buffer, which 
was provided for serum samples.
Measurements of serum substance P 
by radioimmunoassay
Petroleum ether extract 0.2 mL or standard substance P 
were mixed with anti-substance P antibody, and incubated 
at 4 °C overnight. Samples were then incubated with 
125I-tyr8-substance P at 4 °C for 4 h. The mixture was mixed 
with 1% γ-globulin and 17.5% polyethylene glycol, and 
then centrifuged at 3000 rpm at 4 °C for 20 minutes. The 
supernatant was discarded, and the radioactivity of the pellets 
was measured by a γ-counter.
Simple swallowing provocation test
A two-step simple swallowing provocation test (SSPT; 
Teramoto et al 1999) was conducted as a means of assessing 
the aspiration status. A 3Fr feeding tube was inserted to the 
uvula from the nose in a lateral position, and infused once 
with 2 ml of distilled water. If a swallowing reaction occurred 
within 3 seconds, the swallowing reﬂ  ex was judged as posi-
tively induced (p-reﬂ  ex), and if it did not occur, the swallow-
ing reﬂ  ex was judged as negatively induced (n-reﬂ  ex).
Statistical methods
Groups were compared using an unpaired t-test, and χ²-test 
where applicable with p   0.05 indicating a signiﬁ  cant dif-
ference. The values were expressed as the mean ± SD.
Results
Characteristics of subjects
Table shows the basic characteristics of the 22 schizophrenic 
patients who received typical (haloperidol, n = 11; 7 male Neuropsychiatric Disease and Treatment 2008:4(1) 291
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and 4 female) or atypical (risperidone, n = 11; 6 male and 5 
male) antipsychotic drugs. Patients were being treated with 
risperidone or haloperidol, at a mean dosage of 536.3, or 552.2 
mg chlorpromazine per day each, the range going from 3.2 
to 7.6 mg/day (mean 5.4 mg), or from 4.5 to 15.7 mg per day 
(mean 10.1 mg) each. Control subjects consisted of 5 healthy 
adults, aged 38 to 56 years of age (mean 46.2 years; 2 male 
and 3 female). Age, disease duration and BMI were similar 
in each group; no signiﬁ  cant differences were seen among 
three groups in characteristics. The mean chlorpromazine-
equivalent dosages administered to the risperidone and 
haloperidol groups were similar. However, schizophrenia 
patients receiving haloperidol have a tendency to have lesser 
positive episodes of swallowing (7/11; 63.6%) compared to 
those on risperidone (10/11; 90.9%) (Table 1).
Association of serum substance P 
levels with antipsychotic drug use 
and swallowing reﬂ  ex
A possible associations of serum substance P levels with dif-
ferent classes of antipsychotic drugs used for treatment were 
examined, as well as, relationships to episodes of swallowing 
reﬂ  ex using SSPT in patients with schizophrenia. As shown 
in Figure 1, the mean substance P levels were signiﬁ  cantly 
lower in the haloperidol group (20.6 ± 5.5 pg/mL) when com-
pared to the risperidone group (29.0 ± 7.8 pg/mL) (p   0.01). 
Substance P levels for the control subjects (29.6 ± 7.6 pg/mL) 
was not signiﬁ  cantly different than the risperidone group 
(p = 0.8878). No correlation was found for either age or sex 
with serum substance P levels (r = 0.2).
The relationship between the induction of swallowing 
reﬂ  ex and serum substance P levels in all patients receiving 
either haloperidol or risperidone is shown in Figure 2. When 
substance P levels were correlated in all patients based upon 
episodes of reﬂ  ex, higher substance P levels were seen in 
patients with positive episodes of reﬂ  ex (swallowing reﬂ  ex 
elicited, p-Reﬂ  ex; 27.4 ± 7.1 pg/mL) than in patients with 
negative reﬂ  ex (swallowing reﬂ  ex not elicited, n-Reﬂ  ex; 
16.2 ± 1.3 pg/mL) (p   0.001).
Substance P levels were evaluated in patients treated with 
either haloperidol or risperidone and grouped according to 
episodes of reﬂ  ex. Among patients on haloperidol, higher 
substance P levels were seen in patients with positive 
episodes of reﬂ  ex (23.4 ± 4.9 pg/mL) than in patients with 
negative episodes of reﬂ  ex (15.8 ± 1.0 pg/mL) (p   0.01) 
(Figure 3), showing generally lower substance P levels in 
patients on haloperidol, with either positive or negative 
episodes, when compared to patients on risperidone or 
control subjects. In contrast, in the risperidone group, serum 
substance P levels in the majority of patients with positive 
episodes of reﬂ  exes (10/11, 90.9%; 30.1 ± 7.2 pg/mL) was 
found as high as in control subjects all with positive episodes 
(5/5, 100%; 29.6 ± 7.1 pg/mL), and higher than in one patient 
with negative reﬂ  ex (1/11, 9.1%; 18.0 ± 0.0 pg/mL; p   0.01) 
(Figure 3). These results indicate a strong association of 
substance P levels with episodes of reﬂ  ex in patients with 
schizophrenia.
When the association of different classes of antipsychotic 
drug use with episodes of reﬂ  ex was examined, positive 
episodes of reﬂ  ex were higher in patients receiving risperidone 
(90.9%; 10/11) than that in patients receiving haloperidol 
(63.6%; 7/11) (Table 1). It is notable that negative episodes of 
reﬂ  ex in patients receiving haloperidol (4/11; 36.4%) were 4 
times as high as that on risperidone (1/11; 9.1%). In addition, 
in the haloperidol treated subjects, substance P levels, even 
in positive episodes, were found to be relatively lower (23.4 
± 4.9 pg/mL) than either the risperidone (29.0 ± 7.8 pg/mL), 
or on control subjects (29.6 ± 7.6 pg/mL).
Table 1 Baseline characteristics and outcome measures
 Haloperidol  Risperidone  Control  p-value
 N  = 11  N = 11  N = 5 
Age (mean ± SD years)  58.4 ± 6.3  57.5 ± 8.7  46.2 ± 6.5  n.s.*
Gender:  Male/female 7/4 6/5 2/3 
Body mass index   22.0 ± 3.1  21.9 ± 2.7  22.2 ± 1.8  n.s.
Age at illness onset (years)  23.7 ± 3.8  24.4 ± 3.7  N/A**  n.s.
Duration of treatment (month)  25.9 ± 7.7  23.3 ± 7.1  N/A  n.s.
Dose (mg/day)  10.1 ± 5.6  5.4 ± 2.2  N/A 
Chlorpromazine equiv (mg/day)  552.2 ± 317.1  536.3 ± 220.3  N/A  n.s.
Serum substance P (pg/ml)  20.6 ± 5.5  29.0 ± 7.8  29.6 ± 7.6  p   0.01
Positive episodes of swallowing reﬂ  ex  7/11 (63.6%)  10/11 (90.9%)  5/5 (100%)  n.s.
Notes: *Not signiﬁ  cant, **Not applicableNeuropsychiatric Disease and Treatment 2008:4(1) 292
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These results suggest that lower serum substance P levels 
are evoked by the use of haloperidol, resulting in reduction 
of reﬂ  ex. Thus, it appears likely that a low substance P levels 
may potentially contribute to a higher risk of developing 
aspiration in patients with schizophrenia, which may in turn 
lead to increased mortality in patients after antipsychotic 
therapy.
Discussion
The present study has shown that patients on haloperidol, over 
a period of a 14–37 months, were less likely to demonstrate 
positive episodes of swallowing reﬂ  ex (7/11; 63.6%) than 
those on risperidone (10/11; 90.9%) (Table 1). Treatment 
with haloperidol resulted in lower serum substance P levels 
(20.6 ± 5.5 pg/mL) than on risperidone (29.0 ± 7.8 pg/mL; 
p   0.01), which was comparable to untreated, control 
subjects (29.6 ± 7.6 pg/mL; p = 0.9). Among patients on 
haloperidol, those with negative episodes of reﬂ  ex (4/11; 
36.4%) had serum substance P levels at 15.8 ± 1.0 pg/mL 
in contrast with those with positive episodes (7/11; 63.6%) 
who had levels at 23.4 ± 4.9 pg/mL (p   0.01). In contrast, 
in the risperidone treatment group, serum substance P levels 
in the majority of patients with positive episodes of reﬂ  ex 
(10/11, 90.9%; 30.1 ± 7.2 pg/mL) was found to be as high 
as in control subjects all with positive episodes (5/5, 100%; 
29.6 ± 7.6 pg/mL) (p = 0.866), and higher than in one patient 
with negative reﬂ  ex (1/11, 9.1%; 18.0 ± 0.0 pg/mL). These 
results strongly suggest that the use of haloperidol, which 
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Figure 1 Serum substance P levels in antipsychotics-treated patients with schizophrenia and untreated control subjects. Serum substance P levels were measured for 
patients on haloperidol or risperidone, and for control subjects. Horizontal bars represent average levels of serum substance P. Dots represent levels in each individual 
patient.
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Figure 2 Serum substance P levels in all patients with or without episodes of reﬂ  exes. Substance P levels were measured for patients grouped as: with episodes (p-reﬂ  ex) 
or without episodes of reﬂ  exes (n-reﬂ  ex). Vertical bars indicate SD.Neuropsychiatric Disease and Treatment 2008:4(1) 293
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has a potential action of lowering serum substance P levels 
is also associated with lower episodes of swallowing reﬂ  ex. 
The likelihood of developing aspiration pneumonia is directly 
related to the degree of swallowing dysfunctions (Horner 
and Massey 1988; Nakazawa et al 1993; Holas et al 1994). 
The review analyses have shown that typical antipsychotic 
drugs were associated with a signiﬁ  cantly higher risk of death 
than were atypical antipsychotic drugs in elderly psychotic 
patients at all intervals studied (Schneider et al 2005; Wang 
et al 2005). Death mostly results from cardiovascular 
or pneumonia causes (Pontoppidan and Beecher 1960; 
Nakazawa et al 1993). Thus, it seems likely that haloperidol 
increases a risk of developing aspiration, or subsequently 
aspiration pneumonia in schizophrenic patients.
The present study shows a strong association of serum 
substance P levels with episodes of swallowing reflex. 
Human studies have shown that swallowing and cough 
reﬂ  exes are governed by a plexus of nerves containing the 
hormone called substance P (Pernow 1983; Jin 1994). Experi-
mental reduction of substance P using dopamine antagonists 
impairs swallowing (Jin 1994), and patients with impaired 
substance P production have delayed swallowing reﬂ  exes 
and a higher risk of pneumonia (Nakazawa et al 1997). Thus, 
as shown in this study, the failure to induce the swallowing 
reﬂ  ex using the SSPT in schizophrenic patients appears to 
have been strongly attributable to a reduction in substance 
P production.
As many as 40% of patients who aspirate have clini-
cally silent aspiration with no signs or symptoms, indicating 
that the clinical history is often unreliable for determining 
patients at risk for developing aspiration pneumonia (Linden 
and Siebens 1983; Pikus et al 2003). Clinical studies have 
shown that the risk of developing pneumonia is substantially 
higher in patients with silent aspiration compared with those 
in whom aspiration elicits cough and swallowing reﬂ  exes 
(Horner and Massey 1988; Holas et al 1994). It is specula-
tive that serum substance P levels may be a useful predictive 
marker for swallowing difﬁ  culties and for the increased inci-
dence of developing silent aspiration, potentially resulting 
in aspiration pneumonia in elderly patients. Alternatively, 
this increased incidence of silent aspiration may be respon-
sible for increased mortality in schizophrenic patients using 
antipsychotic drugs.
Although the present study does not provide any causal 
relationship between swallowing reflex and substance 
P levels, it has been shown that administration of haloperidol 
signiﬁ  cantly decreases substance P-encoding mRNAs, sug-
gesting a drug-induced decrease in nigrostriatal tachykinin 
biosynthesis (Bannon et al 1986). The present study, com-
bined with these results, suggests that the use of haloperidol 
leads to decreased production of substance P, perhaps due 
to impaired striatal-nigral receptors, and is associated with 
lower levels of swallowing reﬂ  exes.
In conclusion, due to the control that substance P has 
on the swallowing and cough reﬂ  exes, patients on halo-
peridol are at an increased risk of developing aspiration 
or subsequently aspiration pneumonia. In particular, silent 
aspiration may signiﬁ  cantly increase the risk of death in this 
patient group. During treatment with typical antipsychotic 
drugs, a reduction of substance P levels may be predictive 
Figure 3 Substance P levels in patients with or without episodes of reﬂ  exes. Substance P levels were measured according to: with or without episodes of reﬂ  exes on either 
haloperidol or risperidone.Neuropsychiatric Disease and Treatment 2008:4(1) 294
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for developing aspiration, silent aspiration and subsequent 
mortality. Risperidone, which has little inﬂ  uence on serum 
substance P productions, is therefore suggested to be a 
more appropriate ﬁ  rst-line drug of choice for treatment of 
schizophrenia.
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